Intervacc AB (publ) (IVACC.ST)
SEK 0.94
(7.44%)
SEK 0.94
(7.44%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 79.78 Million SEK | 17.71% |
| 2022 | 67.78 Million SEK | 90.18% |
| 2021 | 35.63 Million SEK | 17.55% |
| 2020 | 30.31 Million SEK | -1.33% |
| 2019 | 30.72 Million SEK | -20.03% |
| 2018 | 38.42 Million SEK | 32.72% |
| 2017 | 28.95 Million SEK | 18.88% |
| 2016 | 24.35 Million SEK | -7.99% |
| 2015 | 26.47 Million SEK | 1.67% |
| 2014 | 26.03 Million SEK | 702.53% |
| 2013 | 3.24 Million SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 18.85 Million SEK | 2.55% |
| 2024 Q1 | 18.39 Million SEK | -13.27% |
| 2023 Q1 | 18.23 Million SEK | -14.87% |
| 2023 Q3 | 21.16 Million SEK | 10.36% |
| 2023 Q4 | 21.2 Million SEK | 0.17% |
| 2023 FY | 79.78 Million SEK | 17.71% |
| 2023 Q2 | 19.18 Million SEK | 5.19% |
| 2022 FY | 67.78 Million SEK | 90.18% |
| 2022 Q2 | 17.7 Million SEK | 43.96% |
| 2022 Q1 | 12.29 Million SEK | 20.96% |
| 2022 Q4 | 21.41 Million SEK | 30.88% |
| 2022 Q3 | 16.36 Million SEK | -7.55% |
| 2021 Q2 | 8.4 Million SEK | 6.71% |
| 2021 Q4 | 10.16 Million SEK | 7.0% |
| 2021 FY | 35.63 Million SEK | 17.55% |
| 2021 Q1 | 7.87 Million SEK | -4.05% |
| 2021 Q3 | 9.5 Million SEK | 13.08% |
| 2020 Q3 | 7.4 Million SEK | 1.93% |
| 2020 FY | 30.31 Million SEK | -1.33% |
| 2020 Q2 | 7.26 Million SEK | -2.4% |
| 2020 Q4 | 8.2 Million SEK | 10.8% |
| 2020 Q1 | 7.44 Million SEK | -16.23% |
| 2019 Q4 | 8.88 Million SEK | 22.21% |
| 2019 Q2 | 7.6 Million SEK | 9.04% |
| 2019 Q1 | 6.97 Million SEK | -7.62% |
| 2019 FY | 30.72 Million SEK | -20.03% |
| 2019 Q3 | 7.27 Million SEK | -4.33% |
| 2018 Q2 | 16.1 Million SEK | 130.93% |
| 2018 FY | 38.42 Million SEK | 32.72% |
| 2018 Q4 | 7.54 Million SEK | -3.24% |
| 2018 Q3 | 7.79 Million SEK | -51.59% |
| 2018 Q1 | 6.97 Million SEK | -3.69% |
| 2017 Q4 | 7.24 Million SEK | 4.13% |
| 2017 Q2 | 8.8 Million SEK | 48.12% |
| 2017 FY | 28.95 Million SEK | 18.88% |
| 2017 Q1 | 5.94 Million SEK | -4.42% |
| 2017 Q3 | 6.95 Million SEK | -21.04% |
| 2016 Q2 | 6.48 Million SEK | 8.7% |
| 2016 Q4 | 6.22 Million SEK | 9.45% |
| 2016 FY | 24.35 Million SEK | -7.99% |
| 2016 Q3 | 5.68 Million SEK | -12.32% |
| 2016 Q1 | 5.96 Million SEK | 0.0% |
| 2015 FY | 26.47 Million SEK | 1.67% |
| 2014 FY | 26.03 Million SEK | 702.53% |
| 2013 FY | 3.24 Million SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Calliditas Therapeutics AB (publ) | 1.51 Billion SEK | 94.731% |
| AcouSort AB (publ) | 25.87 Million SEK | -208.336% |
| Active Biotech AB (publ) | 44.8 Million SEK | -78.056% |
| Alzinova AB (publ) | 36.39 Million SEK | -119.214% |
| Amniotics AB (publ) | 29.07 Million SEK | -174.439% |
| Asarina Pharma AB (publ) | 14.65 Million SEK | -444.496% |
| BioArctic AB (publ) | 89.62 Million SEK | 10.981% |
| Camurus AB (publ) | 1.05 Billion SEK | 92.471% |
| Cantargia AB (publ) | 290.01 Million SEK | 72.49% |
| Scandinavian ChemoTech AB (publ) | 21.89 Million SEK | -264.398% |
| Elicera Therapeutics AB (publ) | 28.32 Million SEK | -181.664% |
| Genovis AB (publ.) | 88.19 Million SEK | 9.538% |
| Guard Therapeutics International AB (publ) | 115.07 Million SEK | 30.666% |
| Mendus AB (publ) | 129.13 Million SEK | 38.217% |
| Kancera AB (publ) | 63.07 Million SEK | -26.488% |
| Karolinska Development AB (publ) | 5.51 Million SEK | -1345.642% |
| LIDDS AB (publ) | 27.75 Million SEK | -187.493% |
| Lipum AB (publ) | 37.3 Million SEK | -113.861% |
| Lipigon Pharmaceuticals AB (publ) | 7.25 Million SEK | -999.876% |
| Magle Chemoswed Holding AB (publ) | 135.91 Million SEK | 41.297% |
| Modus Therapeutics Holding AB (publ) | 16.4 Million SEK | -386.464% |
| NextCell Pharma AB | -576.01 Thousand SEK | 13951.106% |
| OncoZenge AB (publ) | 15.9 Million SEK | -401.635% |
| Saniona AB (publ) | 1.07 Million SEK | -7308.078% |
| Simris Alg AB (publ) | 38.64 Million SEK | -106.472% |
| Vicore Pharma Holding AB (publ) | 321.5 Million SEK | 75.184% |
| Xbrane Biopharma AB (publ) | 357.62 Million SEK | 77.69% |
| Xintela AB (publ) | 57.31 Million SEK | -39.202% |
| Ziccum AB (publ) | 27.87 Million SEK | -186.193% |
| Isofol Medical AB (publ) | 7.26 Million SEK | -997.757% |
| Xspray Pharma AB (publ) | 181.73 Million SEK | 56.098% |
| CombiGene AB (publ) | 44.14 Million SEK | -80.738% |
| Diamyd Medical AB (publ) | 142.98 Million SEK | 44.201% |
| Alligator Bioscience AB (publ) | 307.09 Million SEK | 74.019% |
| Sprint Bioscience AB (publ) | 42.63 Million SEK | -87.148% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 17.68 Million SEK | -351.196% |
| Corline Biomedical AB | 30.16 Million SEK | -164.469% |
| IRLAB Therapeutics AB (publ) | 58.03 Million SEK | -37.487% |
| Bio-Works Technologies AB (publ) | 83.16 Million SEK | 4.069% |
| Aptahem AB (publ) | 10.01 Million SEK | -696.819% |
| Infant Bacterial Therapeutics AB (publ) | 134.69 Million SEK | 40.766% |
| Fluicell AB (publ) | 28.61 Million SEK | -178.803% |
| Biovica International AB (publ) | 133.72 Million SEK | 40.335% |
| Spago Nanomedical AB (publ) | 19.79 Million SEK | -303.158% |
| Abliva AB (publ) | 27.86 Million SEK | -186.317% |
| Egetis Therapeutics AB (publ) | 193.5 Million SEK | 58.767% |
| 2cureX AB (publ) | 36.51 Million SEK | -118.481% |
| I-Tech AB | 40.14 Million SEK | -98.727% |
| Hansa Biopharma AB (publ) | 859.44 Million SEK | 90.717% |
| Cyxone AB (publ) | 28.21 Million SEK | -182.785% |
| ExpreS2ion Biotech Holding AB (publ) | 109.36 Million SEK | 27.049% |
| Biosergen AB | 26.8 Million SEK | -197.605% |
| Nanologica AB (publ) | 69.88 Million SEK | -14.163% |
| SynAct Pharma AB | 224.49 Million SEK | 64.46% |
| Annexin Pharmaceuticals AB (publ) | 44.17 Million SEK | -80.607% |
| BioInvent International AB (publ) | 441.4 Million SEK | 81.925% |
| Stayble Therapeutics AB (publ) | 23.95 Million SEK | -233.072% |
| Oncopeptides AB (publ) | 289.74 Million SEK | 72.464% |
| Pila Pharma AB (publ) | 7.85 Million SEK | -915.558% |
| Ascelia Pharma AB (publ) | 110.91 Million SEK | 28.066% |
| Diagonal Bio AB (publ) | 14.7 Million SEK | -442.755% |